1126 related articles for article (PubMed ID: 25182203)
21. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
22. [Idiopathic inflammatory myopathies].
Vencovský J
Vnitr Lek; 2018; 64(2):155-163. PubMed ID: 29595280
[TBL] [Abstract][Full Text] [Related]
23. Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease.
Mammen AL; Casciola-Rosen L; Christopher-Stine L; Lloyd TE; Wagner KR
Neurol Neuroimmunol Neuroinflamm; 2015 Dec; 2(6):e172. PubMed ID: 26668818
[TBL] [Abstract][Full Text] [Related]
24. Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1γ antibodies.
Ueda-Hayakawa I; Tonomura K; Maekawa A; Kaneda E; Arase N; Fujimoto M
J Dermatol; 2023 Aug; 50(8):1058-1062. PubMed ID: 36890683
[TBL] [Abstract][Full Text] [Related]
25. Profiling of Myositis Specific Antibodies and Composite Scores as an Aid in the Differential Diagnosis of Autoimmune Myopathies.
Mahler M; Malyavantham K; Seaman A; Bentow C; Anunciacion-Llunell A; Sanz-Martínez MT; Viñas-Gimenez L; Selva-O'Callaghan A
Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943483
[TBL] [Abstract][Full Text] [Related]
26. [Juvenile dermatomyositis and new autoantibodies: Cases and review].
Guarella M; Jurquet AL; Retornaz K; Bardin N; Chastang MC; Desjonquere M; Fabien N; Belot A
Arch Pediatr; 2015 Dec; 22(12):1263-7. PubMed ID: 26598044
[TBL] [Abstract][Full Text] [Related]
27. Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
Ichimura Y; Konishi R; Shobo M; Inoue S; Okune M; Maeda A; Tanaka R; Kubota N; Matsumoto I; Ishii A; Tamaoka A; Shimbo A; Mori M; Morio T; Kishi T; Miyamae T; Tanboon J; Inoue M; Nishino I; Fujimoto M; Nomura T; Okiyama N
Rheumatology (Oxford); 2022 Mar; 61(3):1222-1227. PubMed ID: 34152410
[TBL] [Abstract][Full Text] [Related]
28. Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China.
Zhao Y; Su H; Yin X; Hou H; Wang Y; Xu Y; Li X; Zhang N; Sun W; Wei W
Med Clin (Barc); 2023 Jan; 160(1):10-16. PubMed ID: 35842306
[TBL] [Abstract][Full Text] [Related]
29. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features.
Yasin SA; Schutz PW; Deakin CT; Sag E; Varsani H; Simou S; Marshall LR; Tansley SL; McHugh NJ; Holton JL; Wedderburn LR; Jacques TS;
Neuropathol Appl Neurobiol; 2019 Aug; 45(5):495-512. PubMed ID: 30378704
[TBL] [Abstract][Full Text] [Related]
30. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
[TBL] [Abstract][Full Text] [Related]
31. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China.
Wen L; Chen X; Cheng Q; Nie L; Xu J; Yan T; Zhang X; Yang H; Sun W; Liu L; Xue J; Du Y
Clin Rheumatol; 2022 Nov; 41(11):3419-3427. PubMed ID: 35859245
[TBL] [Abstract][Full Text] [Related]
32. [The analysis of clinical phenotypes and autoantibodies in juvenile dermatomyositis].
Li DM; Wang L; Liu MY; Xu L; Tang XM
Zhonghua Er Ke Za Zhi; 2020 Dec; 58(12):966-972. PubMed ID: 33256317
[No Abstract] [Full Text] [Related]
33. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
34. New autoantibodies and their clinical associations in juvenile myositis - a systematic review.
Peixoto D; Costa J; Ferretti M; Malattia C; Martini A
Acta Reumatol Port; 2013; 38(4):234-41. PubMed ID: 24435027
[TBL] [Abstract][Full Text] [Related]
35. Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody.
Yan TT; Zhang X; Yang HH; Sun WJ; Liu L; Du Y; Xue J
Clin Rheumatol; 2021 Sep; 40(9):3695-3702. PubMed ID: 33712891
[TBL] [Abstract][Full Text] [Related]
36. [New autoantibodies in dermatomyositis].
Bielsa I
Actas Dermosifiliogr; 2009 Apr; 100(3):182-9. PubMed ID: 19457303
[TBL] [Abstract][Full Text] [Related]
37. Myositis Specific Autoantibodies: A Clinical Perspective.
Alenzi FM
Open Access Rheumatol; 2020; 12():9-14. PubMed ID: 32021502
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Utility of Auto-Antibodies in Inflammatory Muscle Diseases.
Allenbach Y; Benveniste O
J Neuromuscul Dis; 2015; 2(1):13-25. PubMed ID: 28198709
[TBL] [Abstract][Full Text] [Related]
39. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.
Rider LG; Shah M; Mamyrova G; Huber AM; Rice MM; Targoff IN; Miller FW;
Medicine (Baltimore); 2013 Jul; 92(4):223-243. PubMed ID: 23877355
[TBL] [Abstract][Full Text] [Related]
40. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.
Zampeli E; Venetsanopoulou A; Argyropoulou OD; Mavragani CP; Tektonidou MG; Vlachoyiannopoulos PG; Tzioufas AG; Skopouli FN; Moutsopoulos HM
Clin Rheumatol; 2019 Jan; 38(1):125-132. PubMed ID: 30145635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
